OOIR: Observatory of International Research

Papers

(The TQCC of Translational Neurodegeneration is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Retraction Note: Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson’s disease	369
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey	331
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model	204
Exploring the skin as an open window onto neurodegenerative diseases	186
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice	156
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease	122
Retraction Note: Asiaticoside, a trisaccaride triterpene induces biochemical and molecular variations in brain of mice with parkinsonism	115
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants	107
Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application	107
Attenuating α-synuclein pathology in mice with in situ engineered astrocytes	103
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis	101
Impaired dynamic interaction of axonal endoplasmic reticulum and ribosomes contributes to defective stimulus–response in spinal muscular atrophy	96
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients	86
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology	79
Role of dopamine in the pathophysiology of Parkinson’s disease	78
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors	77
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	77
A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease	72
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	71
Defective mitophagy and the etiopathogenesis of Alzheimer’s disease	68
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease	68
Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies	66
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies	65
Cognitive dysfunction of patients infected with SARS-CoV-2 omicron variant in Shanghai, China	64
Correction: Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	64

Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications	63
Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures	60
Targeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer's disease	58
Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity	57
Inflammasomes in neurodegenerative diseases	55
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein	53
Nose-to-brain drug delivery: from bench to bedside	53
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside	52
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease	50
Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson’s and Alzheimer’s disease	50
The emerging role of furin in neurodegenerative and neuropsychiatric diseases	49
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes	47
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study	47
Multidimensional biomarkers for multiple system atrophy: an update and future directions	46
Peripheral proteinopathy in neurodegenerative diseases	46
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter	46
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	46
Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease	46
Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model	45
Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases	45
Aging-dependent YAP1 reduction contributes to AD pathology by upregulating the Nr4a1-AKT/GSK-3β axis	45
Perivascular spaces relate to the course and cognition of Huntington’s disease	44
Improving vulnerable Calbindin1− neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory	44
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system	44
An AARS1 variant identified to cause adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia	43
Targeting galectin-3 to counteract spike-phase uncoupling of fast-spiking interneurons to gamma oscillations in Alzheimer’s disease	43
Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease	42
Deficient AMPK-SENP1-Sirt3 signaling impairs mitochondrial complex I function in Parkinson’s disease model	38
Role of extracellular vesicle-carried ncRNAs in the interactive ‘dialogue’ within the brain and beyond: emerging theranostic epigenetic modifiers in brain-derived nanoplatforms	37
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease	36
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer’s disease and correlates with tau pathology	36
Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson’s disease	36
Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease	35
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis	35
Effects of transcranial ultrasound stimulation pulsed at 40 Hz on Aβ plaques and brain rhythms in 5×FAD mice	35
Plasma proteomic signatures as predictors of dementia risk in individuals with sleep apnea: a cohort study	34
Extracellular PHF-tau modulates astrocyte mitochondrial dynamics and mediates neuronal connectivity	34
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics	34